1.Long-Term Results of Open Heart Surgery in Hemodialysis Patients-CABG vs. Valve Replacement-
Mitsuhiro Yamamura ; Yuji Miyamoto ; Hideki Yao ; Sukemasa Mukai ; Hiroe Tanaka ; Masaaki Ryomoto ; Yoshiteru Yoshioka ; Masanori Kaji
Japanese Journal of Cardiovascular Surgery 2005;34(1):9-13
We evaluated 30 patients who required hemodialysis (HD) before open heart surgery between January 1990 and September 2003. The patients were divided into 2 groups according to surgical procedure: 20 patients underwent coronary artery bypass grafting (CABG group: 14 men and 6 women, mean age, 63 years), and 10 patients underwent valve replacement (VR group: 6 men and 4 women, mean age, 56 years). The mean duration of HD in the CABG group was significantly shorter than that in the VR group (67 months: 121 months, p=0.02). The actual survival rate was calculated by Kaplan-Meier's method. No patient was lost to follow-up. There were 3 hospital deaths in the CABG group (cerebral infarction, arrhythmia, and mediastinitis), and 2 hospital deaths in the VR group (gangrenous cholecystitis and sepsis). There were also 5 late deaths in the CABG group (acute subdural hematoma, pneumonia, AMI, heart failure and gastric cancer) and 4 deaths in the VR group (uterus cancer, 2 intracerebral hemorrhages and PVE). All cardiac event deaths in the CABG group had undergone CABG only with vein grafts. The 4-year actuarial survival rates were 56% (n=5) in the CABG group with a mean follow-up period of 29 months (max 156 months), and 47% (n=3) in the VR group with a mean follow-up period of 35 months (max 131 months). There are 3 points to improve the prognosis of open heart surgery in hemodialysis patients: control of postoperative infection in both groups, prevention of cardiac events in the CABG group and careful anticoagulation therapy in the VR group.
2.Coronary Artery Bypass Grafting in Patients Aged 80 Years or Older
Sukemasa Mukai ; Yuji Miyamoto ; Mitsuhiro Yamamura ; Hiroe Tanaka ; Masaaki Ryomoto ; Yoshiaki Yoshioka ; Masanori Kaji
Japanese Journal of Cardiovascular Surgery 2005;34(5):327-330
Coronary artery bypass grafting (CABG) in elderly patients has been increasing in recent years. Between June 1981, and February 2004, 32 patients aged 80 years or older (mean 81.8) underwent CABG in our hospital. Twenty one patients (67%) were in New York Heart Association class III or IV. Incidence of emergency surgery in the elderly (17 of 32, 53%) was significantly (p<0.0001) higher than that in younger patients (131 of 969, 13.5%). Total hospital deaths were 19% (6 of 32, emergency procedures 5, elective 1). The hospital deaths in patients with an ejection fraction (EF) of 45% or more (5 of 12, 42%) were significantly (p<0.05) higher than those in patients with an EF of more than 45% (1 of 20, 5%). The main features of CABG in octogenarians was the high rate of emergency surgery and high mortality. Thus CABG in octogenarians should be performed early, before the cardiac function deteriorates, in order that treatment not be denied because of age alone.
3.Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study
Koh KITAGAWA ; Akira MITORO ; Takahiro OZUTSUMI ; Masanori FURUKAWA ; Yukihisa FUJINAGA ; Kenichiro SEKI ; Norihisa NISHIMURA ; Yasuhiko SAWADA ; Kosuke KAJI ; Hideto KAWARATANI ; Hiroaki TAKAYA ; Kei MORIYA ; Tadashi NAMISAKI ; Takemi AKAHANE ; Hitoshi YOSHIJI
Clinical Endoscopy 2022;55(3):434-442
Background/Aims:
Covered self-expandable metallic stents (CMSs) are widely used for malignant distal biliary obstructions (MDBOs) caused by pancreatic carcinoma. This study compared the efficacy and safety of the laser-cut-type and braided-type CMSs.
Methods:
To palliate MDBOs caused by pancreatic carcinoma, the laser-cut-type CMSs was used from April 2014 to March 2017, and the braided-type CMSs was used from April 2017 to March 2019. The tested self-expandable metallic stents were equipped with different anti-migration systems.
Results:
In total, 47 patients received CMSs for MDBOs (24 laser-cut type, 23 braided-type). The time to recurrent biliary obstruction (TRBO) was significantly longer in the braided-type CMSs (p=0.0008), and the median time to stent dysfunction or patient death was 141 and 265 days in the laser-cut-type CMSs and braided-type CMSs, respectively (p=0.0023). Stent migration was the major cause of stent dysfunction in both groups, which occurred in 37.5% of the laser-cut-type CMSs and 13.0% of the braidedtype CMSs. There were no differences in the survival duration between the groups.
Conclusions
The TRBO was significantly longer for the braided-type CMSs with an anti-migration system than for the laser-cuttype. Stent migration tended to be less frequent with the braided-type CMSs than with the laser-cut-type CMSs.
4.An Interim Report on Result of Knee Pain Chart Accumulation
Toshikatsu KITADE ; Shoji SHINOHARA ; Masanori AKANUMA ; Fujio ITO ; Jun TANABE ; Masayoshi HYODO ; Akiya KATAOKA ; Kaji SHIBA ; Futami KOSAKA ; Yuji MIYAKE ; Toshifumi TARAHARA ; Zaigen OH ; Toshikazu TAKAGI ; Keiji YOSHIKAWA ; Takumi ITO ; Yasuzo KURONO ; Toru SATO ; Masaaki SHINOHARA ; Hiroshi SANADA ; Katsuhiko MATSUMOTO ; Hiromitsu TANIMURA ; Renpu FUJIMOTO ; Tetsusai YAMAMOTO ; Mitsuru NAKAMURA ; Takao SAKAI ; Tabasu MATSUMOTO ; Takaharu IKEUCHI
Journal of the Japan Society of Acupuncture and Moxibustion 1987;37(4):250-256
5.Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients
Kei MORIYA ; Tadashi NAMISAKI ; Shinya SATO ; Masanori FURUKAWA ; Akitoshi DOUHARA ; Hideto KAWARATANI ; Kosuke KAJI ; Naotaka SHIMOZATO ; Yasuhiko SAWADA ; Soichiro SAIKAWA ; Hiroaki TAKAYA ; Koh KITAGAWA ; Takemi AKAHANE ; Akira MITORO ; Junichi YAMAO ; Hitoshi YOSHIJI
Clinical and Molecular Hepatology 2019;25(4):381-389
BACKGROUND AND AIMS: We previously reported the comparable efficacy of bi-monthly hepatic arterial infusion chemotherapy (B-HAIC) to that of sorafenib chemotherapy for the treatment of advanced hepatocellular carcinoma (aHCC) in patients with compensated cirrhosis. In this study, we demonstrate the efficacy of B-HAIC in patients with decompensated cirrhosis.METHODS: Forty-five patients with aHCC refractory to transcatheter arterial chemo-embolization (TACE) were treated with B-HAIC and were divided into two groups according to hepatic functional reserve (Child-Pugh grade). Overall survival period, treatment response, and adverse events in each group were analyzed.RESULTS: Efficacy and disease control rates in the Child-Pugh B group (n=24; 21% and 71%, respectively) were not significantly impaired compared the Child-Pugh A group (n=21; 38% and 67%, respectively). Median survival time and survival rate at 12 months in the Child-Pugh B group were 422 days and 58.3%, respectively, whereas those in the Child-Pugh A group were 567 days and 70.8%, respectively. Importantly, the hepatic functional reserve of patients did not worsen in either group during the treatment period. Furthermore, the occurrence rate of adverse events leading to discontinuation of anti-tumor treatment was not significantly increased in the Child-Pugh B group.CONCLUSIONS: Given the preservation of hepatic functional reserve afforded by B-HAIC chemotherapy in patients with decompensated cirrhosis, B-HAIC might be an acceptable alternative strategy for aHCC patients who do not respond to TACE.
Carcinoma, Hepatocellular
;
Cisplatin
;
Drug Therapy
;
Fibrosis
;
Humans
;
Liver Cirrhosis
;
Survival Rate
6.Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
Shinya SATO ; Kei MORIYA ; Masanori FURUKAWA ; Soichiro SAIKAWA ; Tadashi NAMISAKI ; Mitsuteru KITADE ; Hideto KAWARATANI ; Kosuke KAJI ; Hiroaki TAKAYA ; Naotaka SHIMOZATO ; Yasuhiko SAWADA ; Kenichiro SEKI ; Koh KITAGAWA ; Takemi AKAHANE ; Akira MITORO ; Yasushi OKURA ; Junichi YAMAO ; Hitoshi YOSHIJI
Clinical and Molecular Hepatology 2019;25(1):65-73
BACKGROUND/AIMS: L-carnitine not only alleviates hyperammonemia and reduces muscle cramps in patients with liver cirrhosis, but also improves anemia in patients with chronic hepatitis and renal dysfunction. This study prospectively evaluated the preventative efficacy of L-carnitine supplementation against hemolytic anemia during antiviral treatment using ribavirin in patients with hepatitis C virus (HCV)-related chronic liver disease. METHODS: A total of 41 patients with chronic hepatitis were consecutively enrolled in this study. Group A (n=22) received sofosbuvir plus ribavirin for 3 months, whereas group B (n=19) was treated with sofosbuvir, ribavirin, and L-carnitine. Hemoglobin concentration changes, the effects of antiviral treatment, and the health status of patients were analyzed using short form-8 questionnaires. RESULTS: A significantly smaller decrease in hemoglobin concentration was observed in group B compared to group A at every time point. Moreover, the prescribed dose intensity of ribavirin in group B was higher than that of group A, resulting in a higher ratio of sustained virological response (SVR) 24 in group B compared with group A. The physical function of patients in group B was also significantly improved compared to group A at the end of antiviral treatment. CONCLUSIONS: L-carnitine supplementation alleviates ribavirin-induced hemolytic anemia in patients with HCV and helps relieve the physical burden of treatment with ribavirin-containing regimens. These advantages significantly increase the likelihood of achieving SVR.
Anemia
;
Anemia, Hemolytic
;
Carnitine
;
Drug Therapy
;
Hepacivirus
;
Hepatitis C
;
Hepatitis C, Chronic
;
Hepatitis
;
Hepatitis, Chronic
;
Humans
;
Hyperammonemia
;
Liver Cirrhosis
;
Liver Diseases
;
Muscle Cramp
;
Prospective Studies
;
Ribavirin
;
Sofosbuvir
7.Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor
Masanori FURUKAWA ; Akira MITORO ; Takahiro OZUTUMI ; Yukihisa FUJINAGA ; Keisuke NAKANISHI ; Koh KITAGAWA ; Soichiro SAIKAWA ; Sinya SATO ; Yasuhiko SAWADA ; Hiroaki TAKAYA ; Kosuke KAJI ; Hideto KAWARATANI ; Tadashi NAMISAKI ; Kei MORIYA ; Takemi AKAHANE ; Junichi YAMAO ; Hitoshi YOSHIJI
Clinical Endoscopy 2021;54(3):371-378
Background/Aims:
Endoscopic resection (ER) for superficial non-ampullary duodenal epithelial tumors (SNADETs) is challenging. Conventional endoscopic mucosal resection (CEMR) is also problematic due to the anatomical features of the duodenum. We compared the safety and efficacy of underwater endoscopic mucosal resection (UEMR) with those of CEMR through a retrospective analysis.
Methods:
Altogether, 44 consecutive patients with 46 SNADETs underwent ER (18 CEMR cases and 28 UEMR cases) between January 2016 and October 2019. We investigated the proportions of en bloc resection, R0 resection, complications, resection time, and total procedure time and compared the outcomes of patients from the CEMR group with those of patients from the UEMR group.
Results:
The median tumor size was 8.0 mm (range, 2.0–20.0 mm). The UEMR group showed a higher proportion of en bloc resection (96.4% vs. 72.2%, p<0.05) and significantly lower median resection time and total procedure time (4 min vs. 9.5 min, p<0.05 and 13 min vs. 19 min, p<0.05; respectively) than the CEMR group. No complications were observed. However, two patients treated with piecemeal resection in the CEMR group had residual tumors.
Conclusions
UEMR is a feasible therapeutic option for SNADETs. It can be recommended as a standard treatment.
8.Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor
Masanori FURUKAWA ; Akira MITORO ; Takahiro OZUTUMI ; Yukihisa FUJINAGA ; Keisuke NAKANISHI ; Koh KITAGAWA ; Soichiro SAIKAWA ; Sinya SATO ; Yasuhiko SAWADA ; Hiroaki TAKAYA ; Kosuke KAJI ; Hideto KAWARATANI ; Tadashi NAMISAKI ; Kei MORIYA ; Takemi AKAHANE ; Junichi YAMAO ; Hitoshi YOSHIJI
Clinical Endoscopy 2021;54(3):371-378
Background/Aims:
Endoscopic resection (ER) for superficial non-ampullary duodenal epithelial tumors (SNADETs) is challenging. Conventional endoscopic mucosal resection (CEMR) is also problematic due to the anatomical features of the duodenum. We compared the safety and efficacy of underwater endoscopic mucosal resection (UEMR) with those of CEMR through a retrospective analysis.
Methods:
Altogether, 44 consecutive patients with 46 SNADETs underwent ER (18 CEMR cases and 28 UEMR cases) between January 2016 and October 2019. We investigated the proportions of en bloc resection, R0 resection, complications, resection time, and total procedure time and compared the outcomes of patients from the CEMR group with those of patients from the UEMR group.
Results:
The median tumor size was 8.0 mm (range, 2.0–20.0 mm). The UEMR group showed a higher proportion of en bloc resection (96.4% vs. 72.2%, p<0.05) and significantly lower median resection time and total procedure time (4 min vs. 9.5 min, p<0.05 and 13 min vs. 19 min, p<0.05; respectively) than the CEMR group. No complications were observed. However, two patients treated with piecemeal resection in the CEMR group had residual tumors.
Conclusions
UEMR is a feasible therapeutic option for SNADETs. It can be recommended as a standard treatment.